Compare YSG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | China | United States |
| Employees | N/A | 14500 |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | YSG | FTRE |
|---|---|---|
| Price | $4.21 | $16.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.07 |
| AVG Volume (30 Days) | 293.5K | ★ 1.4M |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $571,300,568.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $28.96 | $3.17 |
| Revenue Next Year | $16.57 | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.59 | 1.88 |
| 52 Week Low | $3.01 | $3.97 |
| 52 Week High | $11.57 | $20.86 |
| Indicator | YSG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 28.34 | 74.31 |
| Support Level | $4.15 | $15.40 |
| Resistance Level | $5.73 | $16.42 |
| Average True Range (ATR) | 0.41 | 1.02 |
| MACD | -0.11 | 0.19 |
| Stochastic Oscillator | 28.55 | 83.63 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.